Bionano Genomics Inc SEC Filings

Bionano Genomics reported third‑quarter results showing higher revenue and a sharply narrower loss. Q3 2025 revenue was $7.367 million (vs. $6.073 million a year ago), driven by consumables and software, while net loss was $8.503 million (vs. $44.246 million). Cost of revenue fell significantly year over year, and operating expenses dropped without the prior year’s impairment and restructuring charges.

Liquidity remains tight. As of September 30, 2025, the company had $3.065 million in cash and cash equivalents, $18.516 million in investments, and $10.266 million in restricted short‑term investments. Management states there is “substantial doubt” about the company’s ability to continue as a going concern within 12 months without additional financing.

Convertible debentures outstanding totaled $10.266 million in principal, with monthly holder redemptions permitted and a conversion price of $16.20 per share subject to a beneficial ownership cap. Shares outstanding were 9,730,400 at quarter‑end and 10,176,000 as of November 5, 2025.

Bionano Genomics filed a Form 8-K stating it issued a press release reporting financial results for the third quarter ended September 30, 2025. The release is furnished under Item 2.02 and attached as Exhibit 99.1. In accordance with General Instruction B.2., the information in Item 2.02, including Exhibit 99.1, is furnished and not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings unless specifically referenced.

BNGO updated its at-the-market program to permit sales of common stock of up to $9,924,517 through H.C. Wainwright under a Sales Agreement, subject to General Instruction I.B.6 limits.

For I.B.6 purposes, public float was $47,861,922, based on 9,728,033 non‑affiliate shares on October 9, 2025 and a $4.92 price on September 10, 2025. In the prior 12 months, the company sold $6,029,456 of securities under I.B.6; the new capacity excludes those sales. Wainwright will act as sales agent and receive a 3.0% commission on gross proceeds. The shares trade on Nasdaq as BNGO; the closing price was $1.99 on October 16, 2025.

Bionano Genomics (BNGO) received a Schedule 13G disclosing that Lind Global Fund III LP and related reporting persons beneficially own 1,005,961 shares of common stock, representing 9.9% of the class. The disclosed position comprises 525,000 shares, 525,000 Series E warrants and 525,000 Series F warrants, and the filing explicitly states the warrants may not be exercised to cause ownership to exceed 9.9%. The filing identifies Lind Global Partners III LLC as the general partner and Jeff Easton as managing member, with sole voting and dispositive power over the reported holdings. The reporting persons certify the holdings were not acquired to change or influence control.

Bionano Genomics, Inc. reporting persons CVI Investments, Inc. and Heights Capital Management, Inc. disclose collective beneficial ownership of 1,021,671 shares of common stock, representing 9.9% of the class. The reported holdings consist of 475,000 shares plus additional shares issuable upon exercise of warrants, with exercise limited so ownership does not exceed 9.99%.

Heights Capital Management serves as investment manager to CVI Investments and may be deemed to share voting and dispositive power over the reported shares; both entities disclaim beneficial ownership except for pecuniary interest. Exhibits include a Limited Power of Attorney and a Joint Filing Agreement.

Reporting persons Intracoastal Capital LLC, Mitchell P. Kopin and Daniel B. Asher disclose shared beneficial ownership in Bionano Genomics common stock equal to 4.99% of the outstanding class. The filing explains that the ownership position arises from warrants and shares issued or issuable under a Securities Purchase Agreement and that certain warrants include blocker provisions preventing exercise to the extent such exercise would push beneficial ownership above 4.99%. The reporting persons state shared voting and dispositive power over 508,415 shares issuable upon exercise of a warrant and note that, without blocker provisions, their aggregate beneficial interest could be materially larger.

Iroquois Capital Management, LLC and two related individuals disclosed ownership stakes in Bionano Genomics common stock. Iroquois reports beneficial ownership of 367,500 shares (3.8%). Richard Abbe reports aggregate ownership of 525,000 shares (5.4%), and Kimberly Page reports 367,500 shares (3.8%). The filing states that certain warrants exercisable into additional shares (totaling 1,050,000 shares across reporting persons) exist but are subject to 4.99% beneficial ownership blockers that currently prevent their exercise. The cover pages show shared voting and dispositive power for portions of the holdings and clarify that percentages reflect the 9,755,265 shares outstanding referenced in the company prospectus.

Bionano Genomics, Inc. filed a Form 8-K reporting a material corporate event and attached transaction documents. The filing lists exhibit materials that include the Form of Pre-Funded Warrant, Form of Series E/F Warrant, and a Form of Securities Purchase Agreement. It also includes two press releases: one dated September 16, 2025 announcing the pricing of an Offering, and one dated September 17, 2025 announcing the closing of the Offering. The filing provides the company’s registered details and Nasdaq listing (BNGO) but does not disclose transaction amounts, share counts, or other financial terms within the text provided.

Lincoln Alternative Strategies LLC reported beneficial ownership of 525,000 shares of Bionano Genomics, Inc. common stock, representing 5.42% of the 9,680,265 shares outstanding as of September 17, 2025. The filing indicates Lincoln has sole voting and dispositive power over these shares and states the holdings were not acquired to change or influence control of the issuer. The statement is submitted on a Schedule 13G under the Securities Exchange Act.